Want to see AU:BMT full AI Analyst Report?
BMT Stock Chart & Stats
AU$0.12
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.12
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.24
Previous CloseN/A
Volume3.60K
Average Volume (3M)128.91K
Market Cap
AU$27.17M
Enterprise ValueAU$42.22
Total Cash (Recent Filing)AU$2.51M
Total Debt (Recent Filing)AU$4.04M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Feb 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding295,342,600
10 Day Avg. Volume88,730
30 Day Avg. Volume128,909
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.74
Price to Sales (P/S)1.39
P/FCF Ratio52.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside108.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$29.00M
Bulls Say, Bears Say
Bulls Say
Strong Multi-year Revenue GrowthRevenue has expanded substantially over several years, indicating growing adoption of Beamtree’s healthcare software and data solutions. Continued top-line scaling can improve operating leverage, broaden customer reach, and provide a stronger base for future profitability if cost discipline improves.
Low Financial LeverageLow debt relative to equity reduces interest and refinancing pressure, giving the company greater flexibility while it develops its healthcare technology platform. A lightly leveraged balance sheet can also support investment in product development and customer expansion without substantial debt-servicing demands.
Recent Positive Cash GenerationThe recent shift to positive operating and free cash flow is constructive because it indicates the business is beginning to fund operations internally despite reported losses. If sustained, this could reduce dependence on external capital and support ongoing product and service investment.
Bears Say
Persistent Operating And Net LossesThe company has not yet converted strong revenue growth into sustainable earnings, and the particularly large 2026 net loss highlights material profitability pressure. Persistent losses can limit internally funded growth, weaken financial resilience, and make the long-term economics of scaling less certain.
Meaningful Equity ErosionThe substantial reduction in equity is consistent with cumulative losses and represents a meaningful deterioration in the balance-sheet cushion. Unless profitability improves, continued equity drawdown could constrain strategic flexibility and increase the importance of maintaining positive cash generation.
Cash-flow Consistency Remains UnprovenAlthough cash generation turned positive recently, the history of negative operating and free cash flow shows that the improvement has not yet been demonstrated across a full cycle. Volatility can complicate planning, limit reinvestment capacity, and increase reliance on financing if losses persist.
Beamtree Holdings Ltd News
BMT FAQ
What was Beamtree Holdings Ltd’s price range in the past 12 months?
Beamtree Holdings Ltd lowest share price was AU$0.08 and its highest was AU$0.24 in the past 12 months.
What is Beamtree Holdings Ltd’s market cap?
Beamtree Holdings Ltd’s market cap is AU$27.17M.
When is Beamtree Holdings Ltd’s upcoming earnings report date?
Beamtree Holdings Ltd’s upcoming earnings report date is Feb 17, 2027 which is in 138 days.
How were Beamtree Holdings Ltd’s earnings last quarter?
Beamtree Holdings Ltd released its earnings results on Aug 27, 2026. The company reported -AU$0.053 earnings per share for the quarter.
Is Beamtree Holdings Ltd overvalued?
According to Wall Street analysts Beamtree Holdings Ltd’s price is currently Undervalued.
Does Beamtree Holdings Ltd pay dividends?
Beamtree Holdings Ltd does not currently pay dividends.
What is Beamtree Holdings Ltd’s EPS estimate?
Beamtree Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beamtree Holdings Ltd have?
Beamtree Holdings Ltd has 295,342,600 shares outstanding.
What happened to Beamtree Holdings Ltd’s price movement after its last earnings report?
Beamtree Holdings Ltd reported an EPS of -AU$0.053 in its last earnings report. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of Beamtree Holdings Ltd?
Currently, no hedge funds are holding shares in AU:BMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beamtree Holdings Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (108.33% Upside)
AU$0.25 (108.33% Upside)
Blogger Sentiment
Bullish
AU:BMT Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth AU$106.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.14%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Beamtree Holdings Ltd
Headquartered in Redfern, Australia, Beamtree Holdings Limited, founded in 1996, develops and markets cutting-edge clinical decision support (CDS) solutions for the healthcare sector, both within Australia and globally. The company offers a diverse range of products aimed at improving operational accuracy and patient outcomes. Among these are RippleDown Expert, providing live patient monitoring and notification capabilities, and RippleDown Auditor, which automates real-time data verification to ensure precision in billing, data entry, and specimen reception while identifying potential errors. Beamtree also offers PICQ, a quality assessment tool for clinically coded data used by public and private hospitals, health services, and state health authorities, alongside RISQ, designed for the measurement, benchmarking, and management of hospital-acquired complications. Further expanding its suite, the Q Coding Platform delivers an end-to-end workflow for clinical coding, grouping, reporting, and auditing, supported by Codexpert, a digital reference application for classification information in patient records. Additionally, the company provides expert advisory and auditing services, such as desktop analysis, data maturity assessments, and physical audits, reaching its clientele through strategic channel partners. The company adopted its current name, Beamtree Holdings Limited, in August 2021, having previously been known as PKS Holdings Limited.
BMT Stock 12 Month Forecast
Average Price Target
AU$0.25
▲(108.33% Upside)
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Pro Medicus Limited
―
Mach7 Technologies
―
Alcidion Group Limited
―
PainChek Ltd
―







